Skip to main content
Premium Trial:

Request an Annual Quote

NanoDetection Technology Raises $2.3M in Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoDetection Technology and CincyTech today announced that NDT has completed a Series A financing round raising $2.3 million.

The round was oversubscribed as NDT had targeted $2 million.

In total, 21 investors participated in the round. CincyTech led the round with an investment of $400,000 and brought in half a dozen investors into the deal, it and NDT said. Southern Ohio Creates Companies invested $100,000.

Proceeds from the Series A round are expected to fund its clinical trials and plans to get clearance from the US Food and Drug Administration for a test for Staphylococcus aureus. The test is expected to become available in late 2013.

NDT has developed a rapid and cost-effective point-of-care IVD test platform for the detection of pathogens including MRSA, E. coli, salmonella, and listeria, as well as for DNA and other biomarker-based tests, it and CincyTech said.

NDT had been based in Knoxville, Tenn., but moved to Cincinnati last fall. Joel Ivers became its CEO in July 2010.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.